Biochemical pharmacologyTriple Negative Breast NeoplasmsKelch-Like ECH-Associated Protein 1AnimalsB7-H1 AntigenHumans
Artemisinin sensitizes triple negative breast cancer to immune checkpoint therapy through suppressing KEAP1-mediated PD-L1 degradation.
Zehua He, Zhaoshuai Chen, Lei Wang, Ziyi Hu, Zhixin Wang, Jiehang Zhou, Yiran Zhu, Zhaorui Lyu, Wencan Zhang, Fan Lin, Xu Cao, Liqiong Xue
Published: 202610.1016/j.bcp.2026.117682
Abstract
Triple-negative breast cancer (TNBC) remains a clinical challenge due to limited therapeutic options and frequent resistance to immunotherapy. While PD-L1 blockade shows promise, clinical responses are often inadequate. Here we demonstrated that augm…
Preview only. Read the full abstract at the source